Human Vaccines-Infectious & non-Infectious
Finally, the ability of the immune system to recognize a tumor-associated antigen, thus enabling development of a vaccine approach for therapeutic application, represents a main target of this field of research. Long years of research were required for busting the new system to fight cancer. ast year over 800 million doses of combination vaccines are used to vaccinate Chinese children whereas more than 20 million children worldwide do not receive one or more important vaccinations that would protect them from at least one preventable disease. HBV virus, the viola major, the virus that causes the smallpox, lethal virus in the 30% of the cases, was eradicated in 1979 in the human species, thanks to a capillary vaccination on global scale. Thus enabling development of a vaccine approach for therapeutic application represents a main target of this field of research.
- Cancers.
- Systemic lupus erythematous(lupus)
- Certain medicines
- Head injury.
- Brain surgery
- Bacteria Cultures Based Vaccines
Related Conference of Human Vaccines-Infectious & non-Infectious
21th International Conference on Allergic Diseases and Clinical Immunology
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
Human Vaccines-Infectious & non-Infectious Conference Speakers
Recommended Sessions
- Immunopathogenesis
- Allergy, Asthma, and Immunology
- Animal & Plant-Derived Vaccines
- Child immunization and Vaccination Viral Immunology
- Clinical and Diagnostic Immunology
- Current research, and future challenges in vaccines
- DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines
- Geriatric Immunizations
- Human Vaccines-Infectious & non-Infectious
- Immunoinformatics
- Immunological Disorders
- Immunotoxicology
- Neuroendocrine Immunology
- Onco Immunology
- Paediatric Vaccinations
- Pathology and Immunology
- Psychoneuroimmunology
- Stem cell Immunology
- Vaccine & Immunization
- Vaccines against Drugs
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
